As a new-type foreign trade service provider driven by both technology commercialization and foreign trade services, HiSiaddi has established a "1+2+3+4=1" service system and can supply original factory sources of XPhos from multiple well-known brands. As a technology-driven foreign trade enterprise, HiSiaddi has repeatedly resolved customized XPhos product demands for customers through technology transformation cooperation with manufacturers and precise market demand insight. Below is a case of HiSiaddi addressing customized XPhos requirements.
Please contact HiSiaddi customer service if you require more customized service solutions.
The client is a world-leading biopharmaceutical enterprise headquartered in Zurich, Switzerland, specializing in R&D and production of antibody drugs and anti-tumor small molecules. All its products are certified by FDA, EMA and GMP, making it a typical mid-to-high-end client with ultra-high purity, customized and stringent compliance requirements. The company purchases 30 kg of custom-grade XPhos (2-Dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl) annually for core palladium-catalyzed Suzuki coupling reactions. It had long sourced customized products from Merck Germany, but switched to China for customized cooperation in 2025 due to a 14-week lead time, a 30% price hike, and Merck’s refusal to adjust particle size and impurity specifications. The client entrusted HiSiaddi with full coordination for an initial 5 kg customized order.
The client set extremely strict specifications: HPLC purity ≥99.92%, ee value ≥99.9%, heavy metals ≤0.2ppm, residual solvents ≤50ppm, single impurity ≤0.03%, total impurities ≤0.08%. The product must also be sterile, pyrogen-free and endotoxin-free for the synthesis of injectable pharmaceutical intermediates. Conventional domestic XPhos only reaches 98%-99% purity with heavy metals ≤10ppm, failing to meet injectable pharmaceutical grade standards, representing a significant technical gap.
The client required a particle size distribution of 5–15 μm (D90 ≤15 μm), white acicular crystal form, and water content ≤80ppm. The material must be air-stable and resistant to oxidation to match its continuous flow catalytic reactor and avoid particle agglomeration that impairs catalytic efficiency. Most domestic manufacturers produce powdery XPhos with particle sizes ranging from 20–50 μm and lack precise crystal form and particle size customization capabilities.
The client provided an exclusive improved phosphination-coupling synthetic route and mandated strict non-disclosure of the process. Full-process validation from 5 kg lab trials → 50 kg pilot trials → 30 kg mass production was required, with purity, particle size and impurity fluctuations between batches capped at ≤0.05%. A full set of documentation including DMF files, GMP certificates, EU CLP-standard SDS, SVHC test reports, and sterile/pyrogen-free test reports was mandatory for EMA filing.
The client demanded completion of lab trials, pilot trials and delivery of the initial 5 kg batch within 45 days; delays would stall new drug clinical trials. The customized synthetic process involves harsh reaction conditions (-78 °C low temperature, anhydrous and oxygen-free environments) and is prone to substandard purity, abnormal crystal forms and excessive impurities, carrying high failure costs that deterred most domestic manufacturers from taking the order.
HiSiaddi initially contacted 5 mainstream domestic XPhos manufacturers, all of which declined or failed to meet requirements for the following reasons:
1. Technical Shortcomings: Lack of ultra-high-purity purification (multiple recrystallization + high-vacuum distillation), sterile/pyrogen-free treatment and precise crystal form control technologies, unable to hit the 99.92% purity and particle size targets.
2. Confidentiality Concerns: The client’s exclusive synthetic route involves core patents; manufacturers feared process leakage or infringement and refused to sign rigorous non-disclosure agreements.
3. Production Capacity & Consistency Limitations: Most factories only mass-produce industrial-grade XPhos with weak seamless lab-pilot-mass production scaling, unable to guarantee inter-batch stability.
4. Inadequate Compliance Capacity: Unable to provide high-end compliance documents such as DMFs and sterile/pyrogen-free test reports compliant with EU SDS standards, failing EMA requirements.
The client was trapped in a dilemma: Merck Germany raised prices and rejected customization, while Chinese manufacturers could not deliver the product. Delays threatened to halt new drug clinical trials, and the client issued a clear ultimatum to HiSiaddi: resolve all customization hurdles or terminate cooperation.
HiSiaddi assembled a dedicated team of organic synthesis PhDs, high-purity purification specialists, crystal form engineers, compliance officers and confidentiality consultants, and partnered with a hidden champion factory with proven capabilities in custom pharmaceutical-grade phosphine ligands (with prior experience manufacturing premium BINAP and SPhos). A five-dimensional customization framework was formulated: Technical Breakthrough + Confidentiality Safeguards + Full-Process Quality Control + Complete Compliance Support + Strict Lead Time Management, fully implemented within 45 days.
1. Synthetic Process Optimization: Collaborating with the factory’s R&D team, the client’s proprietary route was optimized via precise -78 °C temperature control for low-temperature phosphination, strict anhydrous/oxygen-free atmosphere management, and adjusted catalyst ratios for coupling reactions. This eliminated incomplete reactions and excess byproducts, boosting crude product purity to 99.5%.
2. Ultra-High-Purity Purification: A three-stage purification workflow of multiple recrystallization (anhydrous ethanol-toluene mixed solvent), high-vacuum molecular distillation and activated carbon decolorization was deployed to thoroughly remove heavy metals, residual solvents and chiral impurities. Final purity reached 99.94%, exceeding the client’s minimum 99.92% requirement.
3. Crystal Form & Particle Size Control: White acicular crystals were precisely generated by tuning recrystallization cooling rates (gradual cooling to 25 °C), stirring speeds and solvent ratios. Jet milling and classified screening yielded particle sizes D10=5 μm, D50=9 μm, D90=14 μm, fully matching the 5–15 μm specification.
4. Sterile & Pyrogen-Free Treatment: Sterile filtration via 0.22 μm membranes, depyrogenation and endotoxin removal were performed in a Class 10,000 clean workshop. Test results confirmed endotoxin levels <0.03 EU/mg with full sterility and pyrogen-free compliance for injectable-grade applications.
1. Triple Non-Disclosure Agreements: A tripartite Custom Process NDA was signed between HiSiaddi, the manufacturer and the client, stipulating a EUR 5 million liquidated damages clause for process leakage, restricting technical document access to designated staff only, and prohibiting unauthorized copying or external distribution.
2. Isolated Production Workflows: The factory established a dedicated physically separated clean production line exclusive to this custom product. All core reaction steps were supervised by client-assigned engineers, with key process parameters disclosed solely to the client to prevent technical leaks.
1. Comprehensive Test Standards: Every batch underwent 18 full-item tests including HPLC purity, chiral HPLC ee value, ICP-MS heavy metal analysis, GC residual solvent testing, laser particle size analysis, XRD crystal form identification, Karl Fischer water content measurement, sterility, endotoxin and pyrogen testing. Products could only be released after passing all indicators at 100%.
2. Batch Consistency Verification: Three production scales (5 kg lab trial → 50 kg pilot trial → 30 kg mass production) were validated, with inter-batch purity fluctuations ≤0.03%, particle size fluctuations ≤1 μm and impurity fluctuations ≤0.02%, far exceeding the client’s stability requirements.
3. Authorized Third-Party Testing: Full-scope testing was commissioned to SGS and TÜV to generate traceable, authoritative test reports aligned with FDA/EMA standards.
1. DMF File Compilation: HiSiaddi assisted the factory in organizing customized processes, quality control standards, impurity control protocols and batch records to compile a dedicated XPhos DMF file for the client’s EMA filing.
2. Full-Scope Compliance Document Support: Delivered factory GMP certificates, EU CLP-standard English SDS, SVHC 197-item test reports, sterile/pyrogen-free test reports, batch traceability documents and certificates of origin, fully meeting all client compliance demands.
3. REACH Compliance Guarantee: XPhos REACH pre-registration was completed via a German REACH Only Representative (OR) to obtain a pre-registration number, enabling smooth market access within the EU.
A precise 45-day production schedule was formulated:
· Days 1–7: Process alignment, NDA execution, raw material procurement
· Days 8–15: Lab-scale synthesis, purification optimization, crystal form tuning
· Days 16–25: Pilot scale-up, stability validation, third-party testing
· Days 26–40: Mass production of the initial 5 kg batch, full-scope testing, sterile packaging
· Days 41–45: Document review, shipment, customs clearance escort
Daily progress synchronization was maintained throughout the project, with a 2-hour response window for issues and 24-hour resolution turnaround, ensuring zero delays and on-time delivery within 45 days.
Upon delivery of the initial 5 kg customized XPhos batch, the client completed full-scope testing with the following results:
· Purity: 99.94% (requirement ≥99.92%)
· ee value: 99.93% (requirement ≥99.9%)
· Heavy metals: 0.18 ppm (requirement ≤0.2 ppm)
· Residual solvents: 32 ppm (requirement ≤50 ppm)
· Particle size D90: 14 μm (requirement ≤15 μm)
· Crystal form: White acicular (fully compliant)
· Sterility / Endotoxin: Passed, <0.03 EU/mg (compliant with injectable grade standards)
All indicators met or exceeded requirements. When deployed in catalytic reactions, catalytic efficiency improved by 8% and chiral product purity reached 99.95%, fully replacing Merck Germany’s product with superior performance in several metrics.
The client’s R&D Director commented: “As a world-leading pharmaceutical enterprise, we impose extremely stringent requirements on customized phosphine ligands. We previously believed Chinese manufacturers could not match German technical standards. However, HiSiaddi delivered a flawless solution to our ultra-challenging customization demand within 45 days. Product quality, batch stability and compliance all exceeded our expectations, completely reshaping our understanding of Chinese custom fine chemical manufacturing. Professional, efficient and reliable – HiSiaddi is a core strategic partner within our global supply chain.”
The client awarded HiSiaddi exclusive agency rights for its full-year 30 kg custom XPhos order, at a 22% lower price than Merck Germany with a stable 45-day lead time. Three additional high-end customized phosphine ligands (tert-butyl-XPhos, sulfonated XPhos, etc.) were commissioned to HiSiaddi for integrated customized R&D, manufacturing, quality control and compliance services. A 5-year exclusive customization cooperation agreement was signed, designating HiSiaddi as the sole authorized provider for all Chinese customized phosphine ligand business of the client.
Core pain points for mid-to-high-end client customization include ultra-high purity, extreme impurity control, customized crystal form and particle size, process confidentiality, batch consistency, complete compliance documentation and tight lead times. Such customization carries high technical barriers and substantial failure costs, incomparable to low-end customization requests.
The core value of foreign trade enterprises extends beyond acting as a simple intermediary: they serve as high-end customization resource integrators, technical breakthrough facilitators, compliance guarantors and risk underwriters. Comprehensive capabilities including supplier screening, resource coordination, confidentiality management, quality control oversight and compliance framework construction are required to connect client demand, factory technical capacity and compliant delivery end-to-end.
Key logic for customized services: To serve mid-to-high-end pharmaceutical clients, enterprises must precisely satisfy ultra-rigorous customized specifications, enforce strict process confidentiality, guarantee batch stability, build complete high-end compliance documentation systems and honor lead time commitments. Technical expertise and professional services break client perceptual barriers and enable sustained, deep collaboration.
Please contact HiSiaddi customer service if you require more customized service solutions.
+86-13120989737 
info@hisiaddi.com 
English
